WO2006088955A3 - Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells - Google Patents
Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells Download PDFInfo
- Publication number
- WO2006088955A3 WO2006088955A3 PCT/US2006/005327 US2006005327W WO2006088955A3 WO 2006088955 A3 WO2006088955 A3 WO 2006088955A3 US 2006005327 W US2006005327 W US 2006005327W WO 2006088955 A3 WO2006088955 A3 WO 2006088955A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- cutaneous
- mediated
- lymphocyte antigen
- antigen positive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2007009471A MX2007009471A (en) | 2005-02-14 | 2006-02-14 | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells. |
JP2007555369A JP2008530137A (en) | 2005-02-14 | 2006-02-14 | Methods for treating diseases mediated by cutaneous lymphocyte antigen positive cells |
AU2006214325A AU2006214325B2 (en) | 2005-02-14 | 2006-02-14 | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
CA002595877A CA2595877A1 (en) | 2005-02-14 | 2006-02-14 | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
EP06735136A EP1856150A2 (en) | 2005-02-14 | 2006-02-14 | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
IL184734A IL184734A (en) | 2005-02-14 | 2007-07-19 | Use of an antagonist molecule for preparing a medicament for treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
IL219145A IL219145A0 (en) | 2005-02-14 | 2012-04-15 | Use of an antagonist molecule for preparing a medicament for treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65311405P | 2005-02-14 | 2005-02-14 | |
US60/653,114 | 2005-02-14 | ||
US71676205P | 2005-09-13 | 2005-09-13 | |
US60/716,762 | 2005-09-13 | ||
US74995205P | 2005-12-13 | 2005-12-13 | |
US60/749,952 | 2005-12-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006088955A2 WO2006088955A2 (en) | 2006-08-24 |
WO2006088955A3 true WO2006088955A3 (en) | 2006-11-16 |
Family
ID=36685803
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/005327 WO2006088955A2 (en) | 2005-02-14 | 2006-02-14 | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
PCT/US2006/005328 WO2006088956A2 (en) | 2005-02-14 | 2006-02-14 | Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/005328 WO2006088956A2 (en) | 2005-02-14 | 2006-02-14 | Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists |
Country Status (8)
Country | Link |
---|---|
US (11) | US20060188500A1 (en) |
EP (2) | EP1856150A2 (en) |
JP (2) | JP2008530137A (en) |
AU (2) | AU2006214325B2 (en) |
CA (2) | CA2595877A1 (en) |
IL (3) | IL184734A (en) |
MX (2) | MX2007009471A (en) |
WO (2) | WO2006088955A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9005921B2 (en) | 2007-12-07 | 2015-04-14 | Zymogenetics, Inc. | Polynucleotides encoding IL-31 monoclonal antibodies |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000075314A1 (en) | 1999-06-02 | 2000-12-14 | Chugai Research Institute For Molecular Medicine, Inc. | Novel hemopoietin receptor protein nr10 |
AU7445900A (en) | 1999-09-27 | 2001-04-30 | Chugai Seiyaku Kabushiki Kaisha | Novel hemopoietin receptor protein, nr12 |
PL211833B1 (en) | 2002-01-18 | 2012-06-29 | Zymogenetics Inc | Isolated polypeptide, fusion protein, isolated polynucleotide molecule, expression vector, cultured cell, a method for obtaining the polypeptide, a method for obtaining an antibody, an antibody, an antibody or a fragment thereof, the use of the antibody, a method for detecting the presence of a polypeptide, a method for inhibition the hematopoietic cells proliferation or differentiation, the use of a polypeptide, a method for spreading of hematopoietic cells, a method for detecting RNA presence, a method of killing cancer cells in vitro or in vivo, the use of a polypeptide, the use of a polypeptide, antagonist and a method for detecting infection in a patient |
US10080779B2 (en) | 2004-12-15 | 2018-09-25 | Universite D'angers | Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM |
AU2006207945B2 (en) * | 2005-01-28 | 2012-02-09 | Zymogenetics, Inc. | Homogeneous preparations of IL-31 |
AU2006214404B2 (en) | 2005-02-14 | 2012-03-08 | Bristol-Myers Squibb Company | Methods of treating skin disorders using an IL-31RA antagonist |
WO2006088955A2 (en) * | 2005-02-14 | 2006-08-24 | Zymogenetics, Inc. | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
AU2007254715B2 (en) | 2005-05-06 | 2013-08-29 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists |
BRPI0611069A2 (en) | 2005-05-06 | 2010-11-09 | Zymogenetics Inc | monoclonal antibody, humanized antibody, antibody fragment, use of an antagonist, and hybridoma |
US20130216542A1 (en) | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
PL2047863T3 (en) | 2006-06-08 | 2014-01-31 | Chugai Pharmaceutical Co Ltd | Preventive or remedy for inflammatory disease |
US8466262B2 (en) | 2006-09-01 | 2013-06-18 | Zymogenetics, Inc. | Variable region sequences of IL-31 monoclonal antibodies and methods of use |
US7799323B2 (en) * | 2007-01-10 | 2010-09-21 | Zymogenetics, Inc. | Methods of using IL-31 to treat airway hyper-responsiveness and asthma |
EP2241332A4 (en) | 2007-12-05 | 2011-01-26 | Chugai Pharmaceutical Co Ltd | Therapeutic agent for pruritus |
US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
JP5650871B1 (en) * | 2013-06-28 | 2015-01-07 | 中外製薬株式会社 | Methods for predicting response to treatment with IL-31 antagonists in patients with pruritus-related diseases |
MA43918A (en) * | 2015-04-14 | 2018-12-05 | Chugai Pharmaceutical Co Ltd | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF ATOPIC DERMATITIS CONTAINING AN IL-31 ANTAGONIST AS ACTIVE SUBSTANCE |
KR102641898B1 (en) | 2015-04-14 | 2024-02-27 | 추가이 세이야쿠 가부시키가이샤 | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient |
US10060273B2 (en) | 2015-04-15 | 2018-08-28 | United Technologies Corporation | System and method for manufacture of abrasive coating |
US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
JP2021515800A (en) | 2018-03-16 | 2021-06-24 | ゾエティス・サービシーズ・エルエルシー | Peptide vaccine against interleukin-31 |
JP7449234B2 (en) | 2018-03-16 | 2024-03-13 | ゾエティス・サービシーズ・エルエルシー | Interleukin 31 monoclonal antibody for veterinary use |
WO2019229525A2 (en) * | 2018-04-25 | 2019-12-05 | Kiniksa Pharmaceuticals, Ltd. | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRβ ANTIBODY |
CN117018202A (en) * | 2019-07-08 | 2023-11-10 | 上海交通大学医学院附属瑞金医院 | Novel use of chemokine receptor CCR6 inhibitors for preventing psoriasis recurrence |
RU2707181C1 (en) * | 2019-08-15 | 2019-11-25 | федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Method for prurigo severity prediction by blood tryptase concentration determination method |
KR20220098046A (en) | 2019-11-20 | 2022-07-08 | 추가이 세이야쿠 가부시키가이샤 | Antibody-containing preparation |
KR102392954B1 (en) * | 2020-02-11 | 2022-05-02 | 연세대학교 산학협력단 | Manufacturing method of Avatar Mouse as an Atopic Dermatitis Animal Model, and use thereof |
AU2020466800A1 (en) | 2020-09-01 | 2023-03-23 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing IL-31 antagonist as active ingredient |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030215838A1 (en) * | 2002-01-18 | 2003-11-20 | Sprecher Cindy A. | Cytokine receptor zcytor17 multimers |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5792850A (en) * | 1996-05-23 | 1998-08-11 | Zymogenetics, Inc. | Hematopoietic cytokine receptor |
EP1426059A4 (en) | 2001-09-14 | 2007-01-17 | Ono Pharmaceutical Co | Remedies for pruritus |
PL211833B1 (en) | 2002-01-18 | 2012-06-29 | Zymogenetics Inc | Isolated polypeptide, fusion protein, isolated polynucleotide molecule, expression vector, cultured cell, a method for obtaining the polypeptide, a method for obtaining an antibody, an antibody, an antibody or a fragment thereof, the use of the antibody, a method for detecting the presence of a polypeptide, a method for inhibition the hematopoietic cells proliferation or differentiation, the use of a polypeptide, a method for spreading of hematopoietic cells, a method for detecting RNA presence, a method of killing cancer cells in vitro or in vivo, the use of a polypeptide, the use of a polypeptide, antagonist and a method for detecting infection in a patient |
JP2004219390A (en) * | 2002-02-22 | 2004-08-05 | Taisho Pharmaceut Co Ltd | Method of evaluating medicine having antipruritic effect to atopic dermatitis |
EP1477170A4 (en) | 2002-02-22 | 2007-09-05 | Taisho Pharmaceutical Co Ltd | Antipruritics |
JP2004107209A (en) * | 2002-09-13 | 2004-04-08 | Nippon Oruganon Kk | Therapeutic agent for pruritus |
JP4503942B2 (en) * | 2003-06-11 | 2010-07-14 | 大正製薬株式会社 | Antidiarrheal |
RU2346996C2 (en) | 2004-06-29 | 2009-02-20 | ЮРОПИЭН НИКЕЛЬ ПиЭлСи | Improved leaching of base metals |
AU2006207945B2 (en) | 2005-01-28 | 2012-02-09 | Zymogenetics, Inc. | Homogeneous preparations of IL-31 |
AU2006214404B2 (en) * | 2005-02-14 | 2012-03-08 | Bristol-Myers Squibb Company | Methods of treating skin disorders using an IL-31RA antagonist |
WO2006088955A2 (en) * | 2005-02-14 | 2006-08-24 | Zymogenetics, Inc. | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
AU2007254715B2 (en) * | 2005-05-06 | 2013-08-29 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists |
BRPI0611069A2 (en) | 2005-05-06 | 2010-11-09 | Zymogenetics Inc | monoclonal antibody, humanized antibody, antibody fragment, use of an antagonist, and hybridoma |
US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
WO2007037137A1 (en) * | 2005-09-28 | 2007-04-05 | Konica Minolta Opto, Inc. | Injection molding machine |
TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
US8466262B2 (en) * | 2006-09-01 | 2013-06-18 | Zymogenetics, Inc. | Variable region sequences of IL-31 monoclonal antibodies and methods of use |
US7799323B2 (en) | 2007-01-10 | 2010-09-21 | Zymogenetics, Inc. | Methods of using IL-31 to treat airway hyper-responsiveness and asthma |
HUE036548T2 (en) * | 2007-12-07 | 2018-08-28 | Zymogenetics Inc | Humanized antibody molecules specific for IL-31 |
-
2006
- 2006-02-14 WO PCT/US2006/005327 patent/WO2006088955A2/en active Application Filing
- 2006-02-14 JP JP2007555369A patent/JP2008530137A/en active Pending
- 2006-02-14 MX MX2007009471A patent/MX2007009471A/en not_active Application Discontinuation
- 2006-02-14 EP EP06735136A patent/EP1856150A2/en not_active Withdrawn
- 2006-02-14 US US11/353,454 patent/US20060188500A1/en not_active Abandoned
- 2006-02-14 AU AU2006214325A patent/AU2006214325B2/en not_active Ceased
- 2006-02-14 EP EP06735137.9A patent/EP1856539B1/en not_active Not-in-force
- 2006-02-14 MX MX2007009577A patent/MX2007009577A/en active IP Right Grant
- 2006-02-14 CA CA002595877A patent/CA2595877A1/en not_active Abandoned
- 2006-02-14 US US11/353,427 patent/US20060188499A1/en not_active Abandoned
- 2006-02-14 JP JP2007555370A patent/JP4927762B2/en not_active Expired - Fee Related
- 2006-02-14 WO PCT/US2006/005328 patent/WO2006088956A2/en active Application Filing
- 2006-02-14 CA CA2595939A patent/CA2595939C/en not_active Expired - Fee Related
- 2006-02-14 AU AU2006214326A patent/AU2006214326B2/en not_active Ceased
-
2007
- 2007-07-19 IL IL184734A patent/IL184734A/en not_active IP Right Cessation
- 2007-07-23 IL IL184776A patent/IL184776A/en not_active IP Right Cessation
-
2008
- 2008-09-26 US US12/239,107 patent/US7723048B2/en active Active
-
2009
- 2009-07-02 US US12/497,383 patent/US20090280121A1/en not_active Abandoned
-
2010
- 2010-03-19 US US12/727,912 patent/US8435745B2/en active Active
-
2011
- 2011-04-26 US US13/094,482 patent/US8388964B2/en active Active
-
2012
- 2012-04-15 IL IL219145A patent/IL219145A0/en unknown
-
2013
- 2013-01-30 US US13/754,278 patent/US20130177563A1/en not_active Abandoned
- 2013-03-13 US US13/799,048 patent/US8926957B2/en active Active
-
2015
- 2015-10-09 US US14/879,550 patent/US20160024201A1/en not_active Abandoned
-
2016
- 2016-12-20 US US15/384,774 patent/US20170096484A1/en not_active Abandoned
-
2018
- 2018-10-19 US US16/164,883 patent/US20190040125A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030215838A1 (en) * | 2002-01-18 | 2003-11-20 | Sprecher Cindy A. | Cytokine receptor zcytor17 multimers |
Non-Patent Citations (6)
Title |
---|
BILSBOROUGH ET AL: "IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 117, no. 2, 7 February 2006 (2006-02-07), pages 418 - 425, XP005275428, ISSN: 0091-6749 * |
DILLON STACEY R ET AL: "Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice", NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP,, GB, vol. 5, no. 7, 6 June 2004 (2004-06-06), pages 752 - 760, XP002353112, ISSN: 1529-2908 * |
LEUNG DONALD Y M ET AL: "New insights into atopic dermatitis.", JOURNAL OF CLINICAL INVESTIGATION, vol. 113, no. 5, March 2004 (2004-03-01), pages 651 - 657, XP002392299, ISSN: 0021-9738 * |
SONKOLY ET AL: "IL-31: A new link between T cells and pruritus in atopic skin inflammation", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 117, no. 2, February 2006 (2006-02-01), pages 411 - 417, XP005275427, ISSN: 0091-6749 * |
TAKAOKA A ET AL: "Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 516, no. 2, 31 May 2005 (2005-05-31), pages 180 - 181, XP002392383, ISSN: 0014-2999 * |
TAKAOKA A ET AL: "Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis.", EXPERIMENTAL DERMATOLOGY. MAR 2006, vol. 15, no. 3, March 2006 (2006-03-01), pages 161 - 167, XP004947475, ISSN: 0906-6705 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9005921B2 (en) | 2007-12-07 | 2015-04-14 | Zymogenetics, Inc. | Polynucleotides encoding IL-31 monoclonal antibodies |
US9416184B2 (en) | 2007-12-07 | 2016-08-16 | Zymogenetics, Inc. | Method of treating pruritus with IL-31 monoclonal antibodies |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006088955A3 (en) | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells | |
Schneier et al. | Social anxiety disorder and alcohol use disorder co-morbidity in the National Epidemiologic Survey on Alcohol and Related Conditions | |
Mc Guire et al. | Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis | |
Schaper‐Gerhardt et al. | The role of the histamine H4 receptor in atopic dermatitis and psoriasis | |
WO2005019266A3 (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
WO2004034988A3 (en) | Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors | |
DK1745144T3 (en) | Method of analysis for the detection of drugs on the basis of in vitro differentiated cells | |
JP2008530137A5 (en) | ||
WO2007027761A3 (en) | Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease | |
WO2002015920A3 (en) | Treatment of hyperproliferative diseases | |
WO2005079363A3 (en) | Aptamer therapeutics useful in the treatment of complement-related disorders | |
DE602007008859D1 (en) | BENZOIMIDAZOLE-2-YL PYRIDINES AS HISTAMINE H4 RECEPTOR MODULATORS | |
WO2006012641A3 (en) | Methods for detecting and treating autoimmune disorders | |
WO2007035489A3 (en) | Methods of treating or preventing cancer using pyridine carboxaldehyde pyridine thiosemicarbazone radiosensitizing agents | |
Fujii et al. | Effects of the Janus kinase inhibitor CP-690550 (tofacitinib) in a rat model of oxazolone-induced chronic dermatitis | |
Vakharia et al. | Monoclonal antibodies for atopic dermatitis: Progress and potential | |
Renert-Yuval et al. | Monoclonal antibodies for the treatment of atopic dermatitis | |
Saad et al. | The c-Met inhibitor capmatinib alleviates acetaminophen-induced hepatotoxicity | |
WO2004038381A3 (en) | Methods for drug discovery, disease treatment, and diagnosis using metabolomics | |
Wagner et al. | Rapamycin analogs with reduced systemic exposure | |
SE0402536D0 (en) | Immunoregulation in cancer, chronic inflammatory and autoimmune diseases | |
Eddie et al. | Selective pharmaceutical inhibition of PARP14 mitigates allergen-induced IgE and mucus overproduction in a mouse model of pulmonary allergic response | |
Baliou et al. | Bromamine T, a stable active bromine compound, prevents the LPS‑induced inflammatory response | |
Cooper et al. | Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia (wAIHA): A Phase 3, randomized, double-blind, placebo-controlled, global study | |
Merega et al. | Antibody/receptor protein immunocomplex in human and mouse cortical nerve endings amplifies complement-induced glutamate release |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 184734 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2595877 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006214325 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/009471 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007555369 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006214325 Country of ref document: AU Date of ref document: 20060214 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006735136 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3999/CHENP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 219145 Country of ref document: IL |